BridgeBio Pharma BBIO Payments to Acquire Intangible Assets
Payments to Acquire Intangible Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's payments to acquire intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's payments to acquire intangible assets?
- BridgeBio Pharma (BBIO) reported payments to acquire intangible assets of $0 in Q1 2026.
- How has BridgeBio Pharma's payments to acquire intangible assets changed year-over-year?
- BridgeBio Pharma's payments to acquire intangible assets decreased by 100.0% year-over-year, from $1.6M to $0.
- What is the long-term trend for BridgeBio Pharma's payments to acquire intangible assets?
- Over 4 years (2021 to 2025), BridgeBio Pharma's payments to acquire intangible assets has grown at a -29.8% compound annual growth rate (CAGR), from $35M to $8.5M.